SLRN Share Price Performance
US$2.27
-3.68 (-61.85%)
Price US$2.27
Share PriceUS$2.27
Acelyrin, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
SLRN Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Acelyrin, Inc. Key Details
About SLRN
- Founded
- 2020
- Employees
- 83
- CEO
- WebsiteView website
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company’s lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
